Samsung Bioepis’ Lucentis Biosimilar (SB11)' phase III completed. Lucentis' global sales last year were about ￦4.2 trillion.

Samsung Bioepis recently announced its last patient visit for the SB11 phase III trial was done.

Phase III examined compared non-inferiority with the original Lucentis in a total of 705 patients with Wet Age-related Macular Degeneration from Mar 2018.

Lucentis is a treatment for eye diseases such as macular degeneration and diabetic macular edema, jointly developed by Roche’s subsidiary Genentech and Novartis, multinational pharmaceuticals.

Samsung Bioepis plans to announce the results of phase III next year and proceed wit